11-Sep-2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
Globe Newswire (Thu, 23-Jul 4:05 PM ET)
Abivax Announces Closing of $920 Million Public Offering
Globe Newswire (Mon, 6-Jul 4:05 PM ET)
Market Chameleon (Thu, 2-Jul 7:44 AM ET)
Globe Newswire (Thu, 2-Jul 2:00 AM ET)
Globe Newswire (Wed, 1-Jul 9:06 AM ET)
Market Chameleon (Wed, 1-Jul 4:58 AM ET)
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Globe Newswire (Wed, 1-Jul 8:56 AM ET)
Globe Newswire (Wed, 1-Jul 8:37 AM ET)
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Globe Newswire (Wed, 1-Jul 1:30 AM ET)
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Abivax SA - American Depositary Shares trades on the NASDAQ stock market under the symbol ABVX.
As of September 11, 2026, ABVX stock price climbed to $118.64 with 847,382 million shares trading.
ABVX has a beta of 1.73, meaning it tends to be more sensitive to market movements. ABVX has a correlation of 0.09 to the broad based SPY ETF.
ABVX has a market cap of $10.35 billion. This is considered a Large Cap stock.
Last quarter Abivax SA - American Depositary Shares reported $5 million in Revenue and -$5.45 earnings per share. This fell short of revenue expectation by $-348,000 and missed earnings estimates by -$.54.
The top ETF exchange traded funds that ABVX belongs to (by Net Assets): ATFV, VXUS, VEA, MSSM, ONEQ.
ABVX has outperformed the market in the last year with a price return of +35.4% while the SPY ETF gained +18.3%. ABVX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.0% and +3.8%, respectively, while the SPY returned +5.6% and -0.9%, respectively.
ABVX support price is $113.24 and resistance is $118.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVX shares will trade within this expected range on the day.